Eli Lilly (LLY)
1,040.00
+3.46 (0.33%)
NYSE · Last Trade: Feb 15th, 2:32 PM EST
It's an easy way to quickly own 150-plus companies growing at a solid clip.
Via The Motley Fool · February 15, 2026
Eli Lilly isn't a one-trick pony.
Via The Motley Fool · February 15, 2026
Eli Lilly continues to pursue smart acquisitions for the long term.
Via The Motley Fool · February 14, 2026
Growth, value, or both?
Via The Motley Fool · February 14, 2026
Novo is looking to ensure the U.S. market is supplied before choosing another country to scale in, Doustdar said in an interview with CNBC.
Via Stocktwits · February 13, 2026
The U.S. labor market kicked off 2026 with an unexpected surge, as the January nonfarm payrolls report shattered analyst expectations and provided a much-needed jolt to the economic outlook. Adding 130,000 jobs—nearly double the consensus forecast of 65,000—the "blowout" report signals that the American economy
Via MarketMinute · February 13, 2026
In a day defined by sharp reversals and a fundamental recalibration of market leadership, the healthcare sector emerged as the primary beneficiary of a massive capital rotation on February 13, 2026. While the broader indices grappled with a "valuation reset" triggered by shifts in Federal Reserve leadership and a cooling
Via MarketMinute · February 13, 2026
Eli Lilly announced an acquisition of an innovative new autoimmune drug.
Via The Motley Fool · February 13, 2026
As the opening bell rang on February 13, 2026, the divergence between the U.S. technology and healthcare sectors reached a historic fever pitch, signaling a fundamental shift in how markets price growth and defense. While the technology sector continues to ride a wave of massive capital investment into artificial
Via MarketMinute · February 13, 2026
Pfizer's long-acting GLP-1 weight loss candidate could set the stage for a stock rally.
Via The Motley Fool · February 13, 2026
Eli Lilly and Company (NYSE: LLY) has stockpiled $1.5 billion worth of inventory of its experimental oral weight-loss drug, orforglipron, according to a regulatory filing on Thursday.
Via Benzinga · February 13, 2026
Data on Stocktwits showed retail traders remained bearish on SPY and ‘extremely bearish’ on QQQ.
Via Stocktwits · February 13, 2026
On February 11, 2026, Meta Platforms Inc. (NASDAQ: META) officially broke ground on a sprawling $10 billion data center campus in Lebanon, Indiana, marking a monumental shift in the company’s infrastructure strategy. The 1-gigawatt (1GW) facility, situated within the state’s burgeoning LEAP Research and Innovation District, is designed
Via MarketMinute · February 12, 2026
As of February 12, 2026, the financial landscape has undergone a tectonic shift, with the healthcare sector decisively seizing the mantle of market leadership. After years of dominance by high-flying technology giants, investors have executed a massive "Great Rotation," fleeing overextended tech valuations in favor of the stability and renewed
Via MarketMinute · February 12, 2026
Novo Nordisk plans to sell Wegovy in vials in the U.S., expanding options as it competes with Eli Lilly in the growing weight-loss drug market.
Via Benzinga · February 12, 2026
The healthcare sector has staged a dramatic structural breakout, ending a multi-year period of relative stagnation to lead the global markets into 2026. After a powerful 10% gain in the final quarter of 2025, the sector has officially surpassed technology and energy to become the top-performing segment of the S&
Via MarketMinute · February 12, 2026
As the global economy stabilizes into a period of disinflationary growth, Goldman Sachs (NYSE: GS) has released a robust 2026 stock market outlook, forecasting a 12% total return for the S&P 500. This optimistic projection, which places the index target between 7,200 and 7,600 by year-end, suggests
Via MarketMinute · February 12, 2026
Both companies are betting on interest in weight loss pills.
Via The Motley Fool · February 12, 2026
Generating cash is essential for any business, but not all cash-rich companies are great investments.
Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
Via StockStory · February 11, 2026
Energy stocks are in the spotlight, and ExxonMobil is best in breed.
Via The Motley Fool · February 11, 2026
The company shared optimistic timelines for advancing the clinical studies of both oral and subcutaneous VK2735 in obesity.
Via Stocktwits · February 11, 2026
Bloomberg reported on Wednesday, citing Novo CEO Mike Doustdar, that the vials are slated to be introduced in the U.S. this year.
Via Stocktwits · February 11, 2026
The healthcare leader looks increasingly unstoppable.
Via The Motley Fool · February 11, 2026
Disney has hired a new CEO, with Josh D'Amaro taking over for Bob Iger in March.
Via The Motley Fool · February 11, 2026
Eli Lilly is priced for perfection thanks to its GLP-1 drugs, while Wall Street seems to have forgotten about these two high-yield healthcare stocks.
Via The Motley Fool · February 11, 2026